Adam Robertson

Dr Adam Robertson is Chief Scientific Officer of Hemispherian, where he leads development of the company’s first-in-class GLIX platform of small-molecule therapeutics targeting DNA-repair vulnerabilities in glioblastoma and other solid tumours. With more than 20 years’ experience in scientific research and drug discovery, he holds a PhD from the University of North Carolina at Chapel Hill and went on to establish his own research laboratory at Oslo University Hospital. His work centres on translating novel oncology candidates from preclinical models into the clinic, including GLIX1, now in first-in-human Phase 1/2a trials for glioblastoma through Hemispherian’s partnership with BioLineRx.